Compounded semaglutide associated with at least 10 deaths, Novo Nordisk CEO warns
Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 hospitalizations and 10 deaths, the chief executive of Ozempic maker Novo Nordisk warned Wednesday.
Compounded Versions Of Weight Loss And Diabetes Drugs Led To Death And Hospitalization, Novo Nordisk Says It Is Aware
Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including reports of deaths and hospitalizations, while working with the FDA to resolve issues.
Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump
Novo Nordisk reported on Wednesday better-than-expected quarterly sales of its popular Wegovy weight-loss drug, reassuring investors worried the drugmaker was losing its lead in the fast-growing obesity drug market to U.
Novo Nordisk Stock Rises After Earnings. Weight-Loss Drug Wegovy Sales Beat Estimates.
Ozempic sales were a bit lower than expected in the quarter at DKK 29.8 billion, while Wegovy sales were higher at DKK 17.3 billion. The obesity drug market is currently dominated
Obesity drug maker Novo Nordisk posts strong profit
Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted Wednesday strong third-quarter earnings despite being held back by production constraints.
Novo Nordisk is aware of 10 deaths from compounded weight-loss drug copies
Novo Nordisk is aware of 100 hospitalizations and 10 deaths resulting from people taking compounded copies of its popular weight-loss and diabetes drugs, the drugmaker's finance chief said on Wednesday.
Novo Nordisk Posts Solid Earnings. Weight-Loss Drug Wegovy Sales Beat Estimates.
When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated the market for the new GLP-1 weight-loss medicines. W
Novo Nordisk aware of 10 deaths related to weight-loss drug copies - report
Novo Nordisk (NVO) is aware of 10 deaths and 100 hospitalizations of people that took copycat versions of its popular drugs Wegovy and Ozempic, its CFO Karsten Munk Knudsen told a media
Novo Nordisk CEO Warns of Deaths Linked to Compounded Semaglutide
The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...
Scientist behind Novo Nordisk's Ozempic, Wegovy started her career developing laundry detergent
Novo Nordisk scientist Lotte Knudsen, whose research led to Ozempic and Wegovy, started her career developing laundry ...
Ozempic maker Novo Nordisk is working on a once-monthly weight-loss drug
Novo Nordisk (NVO), the maker of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, has entered an agreement with ...
FiercePharma21h
After Lilly's GLP-1 sales fumble, Novo reports mixed results on Ozempic, Wegovy
Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...
Investor's Business Daily on MSN18h
Novo Nordisk Dips After Tightening Its Outlook As Wegovy Beats, But Ozempic Misses
Novo Nordisk stock inched down Wednesday after the drugmaker's weight-loss drug beat forecasts, but sales of its diabetes behemoth missed.
Ozempic, Wegovy sales inject wealth into Novo Nordisk home country of Denmark
Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide— while adding great ...
STAT7d
Novo Nordisk’s Ozempic and Wegovy, long in shortage, are now listed as available by FDA
Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...
NBC New York7d
Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
All doses of Novo Nordisk's weight loss injection Wegovy and diabetes drug Ozempic are now available in the U.S., according to an update on the FDA's drug shortage database. It is a sign that ...
What Wall Street Analysts Think of Novo Nordisk's Stock Ahead of Earnings
Novo Nordisk reports earnings Wednesday morning, with sales of blockbuster weight-loss drugs Ozempic and Wegovy expected to continue driving the Danish drugmaker's results higher.
Ozempic/Wegovy Maker Maintains Q3 Sales Growth On Booming Demand
On Wednesday, Novo Nordisk A/S (NYSE:NVO) reported third-quarter 2024 sales of 71.311 billion Danish kroner (around $10.3 ...